



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com

Ref. No: ADL/2-K/2013

Date : 14th November, 2013.

To, The Department of Corporate Services Bombay Stock Exchange Ltd., Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE Code: 524348	To, The Secretary The National Stock Exchange of India Ltd., Exchange Plaza, 5 th Floor, Plot No.C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE Scrip: AARTIDRUGS
--	--

Dear Sirs,

Ref.: Compliance of Clause 41 of the Listing Agreement.

Sub: Audited Financial Results for the quarter and half year ended 30th September, 2013.

In terms of Clause 41 of the Listing Agreement, we are forwarding herewith the Audited Financial Results along with Auditor's Report on Financial Results of the Company for the quarter and half year ended 30th September, 2013 in the prescribed form which have been taken on record by the Board of Directors of the Company at its meeting held on Thursday, 14th November, 2013 at Mumbai.

Further, please note that the Company has already made necessary arrangement to publish the same in the newspapers as required under the Listing Agreement.

Please take note of the same on your record.

Thanking you,

Yours faithfully,
For **AARTI DRUGS LIMITED**

SUNNY PAGARE
COMPANY SECRETARY

Encl: as above.



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com

AARTI DRUGS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2013

PART I		(Rs. in Lacs except for share data)					
		Quarter Ended			Half Year Ended		
		30th Sept, 2013	30th June, 2013	30th Sept, 2012	30th Sept, 2013	30th Sept, 2012	31st March, 2013
Sr. No.	Particulars	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Income from Operations						
	(a) Gross Sales / Income from Operations	26,627	23,527	23,266	50,154	43,655	88,575
	Less : Excise Duty & Sales Tax	1,847	1,668	1,633	3,515	3,037	6,091
	(a) Net Sales / Income from Operations (Net Of Excise Duty & Sales Tax)	24,780	21,859	21,634	46,639	40,618	82,484
	(b) Other Operating Income	15	5	6	21	8	91
	Total income from operations (net)	24,795	21,865	21,640	46,660	40,626	82,575
2	Expenditure						
	(a) Cost of materials consumed	16,453	13,088	13,085	29,541	25,111	49,244
	(b) Purchase of stock-in-trade	2,564	2,483	2,387	5,046	4,325	6,543
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,881)	(577)	(648)	(2,458)	(1,660)	(2,259)
	(d) Employee benefits expense	832	740	667	1,572	1,317	2,853
	(e) Depreciation and Amortisation Expense	684	669	640	1,353	1,273	2,598
	(f) Other expenses	3,307	3,030	3,191	6,336	5,987	12,161
	Total expenses	21,958	19,433	19,323	41,391	36,353	73,140
3	Profit from Operations before Other income, finance costs and exceptional items (1-2)	2,837	2,432	2,317	5,269	4,273	9,435
4	Other Income	-	-	-	-	-	-
5	Profit from ordinary activities before finance cost and exceptional items (3+4)	2,837	2,432	2,317	5,269	4,273	9,435
6	Finance costs (interest)	780	728	660	1,508	1,311	2,804
7	Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	2,057	1,704	1,657	3,760	2,963	6,631
8	Exceptional Items	-	-	-	-	-	-
9	Profit from Ordinary Activities before Tax (7-8)	2,057	1,704	1,657	3,760	2,963	6,631
10	Tax Expenses (Includes)	772	520	495	1,292	914	2,064
	Provision for Taxation - Current	615	440	415	1,055	770	1,760
	- Earlier year	67	-	-	67	-	-
	Provision for Deferred Taxation	90	80	80	170	144	304
11	Net profit from ordinary Activities after Tax (9-10)	1,284	1,184	1,162	2,468	2,049	4,567
12	Extraordinary items	92	-	-	92	-	(44)
13	Net Profit for the Period (11+12)	1,376	1,184	1,162	2,560	2,049	4,524
14	Paid-up Equity Share Capital of Rs.10/- each.	1,211	1,211	1,211	1,211	1,211	1,211
15	Reserves & Surplus (excluding revaluation reserves)	-	-	-	-	-	19,550
16	Earning per share (of Rs. 10 /- each) (not annualised)						
	Basic & Diluted	11.36	9.78	9.59	21.14	16.92	37.36
PART II							
A PARTICULARS OF SHAREHOLDING							
1	Public shareholding						
	-Number of Shares	5,024,311	5,044,266	5,269,645	5,024,311	5,269,645	5,154,122
	-Percentage of Total Shareholding	41.49	41.66	43.52	41.49	43.52	42.57
2	Promoters & Promoter Group shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total Share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered						
	- Number of Shares	7,084,239	7,064,284	6,838,905	7,084,239	6,838,905	6,954,428
	- Percentage of shares (as a % of the total Shareholding of promoter and promoter group)	100	100	100	100	100	100
	- Percentage of shares (as a % of the total Share capital of the company)	58.51	58.34	56.48	58.51	56.48	57.43
B INVESTOR COMPLAINTS		Quarter Ended 30th September, 2013					
	Pending at the beginning of the quarter	0					
	Received during the quarter	3					
	Disposed of during the quarter	3					
	Remaining unresolved at the end of the quarter	0					



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2013 (Rs. in lacs)

Particulars	As at 30th September, 2013	As at 31st March, 2013
A EQUITY AND LIABILITIES		
1 Shareholder funds	1,211	1,211
(a) Share Capital	21,685	19,550
(b) Reserves and surplus		
A Sub - total - Shareholder's funds	22,896	20,761
2 Non-current liabilities	7,892	8,070
(a) Long - term borrowings	2,921	2,751
(b) Deferred tax liabilities (net)	863	1,003
(c) Other long - term liabilities	584	286
(d) Long - term provisions	12,260	12,111
Total - Non - current liabilities		
3 Current liabilities	24,696	21,498
(a) Short - term borrowings	12,319	13,189
(b) Trade payables	3,720	3,024
(c) Other current liabilities	2,173	1,389
(d) Short - term provisions	42,908	39,100
Total - current liabilities	78,064	71,972
TOTAL- EQUITY AND LIABILITIES		
B ASSETS		
1 Non-current assets	32,922	30,382
(a) Fixed assets (including CWIP)	513	513
(b) Non - current investments	1,408	256
(c) Long - term loans and advances		
Total - Non - current assets	34,843	31,151
2 Current assets	16,767	14,092
(a) Inventories	22,436	21,567
(b) Trade receivables	215	288
(c) Cash and cash equivalents	1,667	1,960
(d) Short - term loans and advances	2,136	2,913
(e) Other non - current assets	43,221	40,821
Total - current assets	78,064	71,972
TOTAL - ASSETS		

Notes:

- The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 14th November, 2013.
- The Board of Directors have declared Interim Dividend of Rs.3/- per equity shares of Rs. 10/- each amounting to Rs.36325650/- and 20th November, 2013 has been fixed as record date for the payment of said interim dividend.
- Pollution Control Authority had issued notices for shutting manufacturing operations to various units located in Tarapur. Four out of nine plants of the Company had to shut its operations due to this from 21.10.2013. Based on the steps taken by the Company, three plants have already commenced operations on 02.11.2013 and 13.11.2013 respectively and fourth plant is expected to commence operations soon.
- Company is operating as a Single Segment Company, engaged in Pharmaceuticals Business.
- Figures for the previous period have been regrouped or rearranged wherever necessary.

Place : Mumbai
Date: 14th November, 2013

For and on behalf of the Board
For AARTI DRUGS LIMITED

HARSHIT M. SAVLA
(JT. MANAGING DIRECTOR)



PARIKH JOSHI & KOTHARE (Regd.)

CHARTERED ACCOUNTANTS

49/2341, M.H.B. Colony, Gandhi Nagar, Bandra (East), Mumbai - 400 051.

☎ : +91-022-2651 5396 / 2645 1439 • Fax : +91-022-2645 5867 • E-mail : pjkbandra@yahoo.co.in • Website : www.pjkca.com

Auditor's Report On Quarterly Financial Results and Year to Date Results of AARTI DRUGS LIMITED Pursuant to the Clause 41 of the Listing Agreement

To

Board of Directors of AARTI DRUGS LIMITED

We have audited the quarterly financial results of AARTI DRUGS LIMITED for the quarter ended 30th September 2013 and the year to date results for the period 1st April 2013 to 30th September 2013, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per section 211(3C) of the Companies Act, 1956 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.




In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 30th September 2013 and the year to date results for the period 1st April 2013 to 30th September 2013.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For Parikh Joshi & Kothare
Chartered Accountants



CA TEJAS J. PARIKH
PARTNER

M.No. 123215

Firm Registration No. 107547W

Mumbai, Dated: November 14th, 2013

